Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Morgan Stanley from $147.00 to $151.00. They now have an "overweight" rating on the stock.
Cantor Fitzgerald Maintains a Buy Rating on Gilead Sciences (GILD) [Yahoo! Finance]
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at HSBC Holdings plc from $110.00 to $133.00. They now have a "hold" rating on the stock.
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Wells Fargo & Company from $145.00 to $150.00. They now have an "overweight" rating on the stock.
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer